Publication at Second Faculty of Medicine |
2013
Abstract
Asparaginases are important agents used in the treatment of children with acute lymphoblastic leukemia (ALL). Three types of asparaginase are currently available: two are derived from Escherichia coli [native asparaginase and pegylated asparaginase (PEG-asparaginase)] and one from Erwinia chrysanthemi (crisantaspase).
All three products share the same mechanism of action but have different pharmacokinetic properties, which do not make them easily interchangeable.